EMEA-002292-PIP01-17
Key facts
| Active substance |
Rovalpituzumab tesirine
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0116/2018
|
| PIP number |
EMEA-002292-PIP01-17
|
| Pharmaceutical form(s) |
Powder and solvent for concentrate for solution for infusion
|
| Condition(s) / indication(s) |
Treatment of lung carcinoma (small cell and non-small cell carcinoma)
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
AbbVie Ltd
E-mail: paediatricteam@abbvie.com |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|